OverviewSuggest Edit

Alcon is an eye care device company. It operates through two segments: Surgical and Vision Care. The Surgical segment offers technologies and devices for cataract, retinal, refractive surgery, as well as advanced technology intraocular lenses (ATIOLs) to treat cataracts and refractive errors, like presbyopia and astigmatism. It also provides viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery. The Vision Care segment offers a range of daily disposable, reusable and color-enhancing contact lenses and products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers.

TypePublic
Founded1945
HQVernier, CH
Websitealcon.com
Employee Ratings3.9
Overall CultureA

Latest Updates

Employees (est.) (Dec 2019)22,142(+9%)
Revenue (FY, 2020)$6.8 B(-8%)
Share Price (May 2021)CHF64.2(-7%)
Cybersecurity ratingBMore

Key People/Management at Alcon

David Endicott

David Endicott

Chief Executive Officer & Director
Ian Bell

Ian Bell

President, International
Heather Attra

Heather Attra

SVP, Head Global Quality
Laurent Attias

Laurent Attias

SVP, Head Global Corp Dev Strategy, BD&L, and M&A
Tim Stonesifer

Tim Stonesifer

SVP, Chief Financial Officer
Franck Leveiller

Franck Leveiller

SVP, Head Global R&D
Show more

Alcon Office Locations

Alcon has offices in Vernier, Cointrin, Fribourg, Schaffhausen and in 25 other locations
Vernier, CH (HQ)
Chemin de Blandonnet 8
Cointrin, CH
Avenue Louis-Casaï 58
Fribourg, CH
Rue Louis-d'Affry 6
Schaffhausen, CH
Winkelriedstrasse 52
Zug, CH
Dammstrasse 21
Macquarie Park, AU
Suite 1, Level 7/15 Talavera Rd
Show all (29)

Alcon Financials and Metrics

Alcon Revenue

Embed Graph
View revenue for all periods
Alcon's revenue was reported to be $6.83 b in FY, 2020 which is a 9% decrease from the previous period.
USD

Revenue (FY, 2020)

6.8b

Revenue growth (FY, 2019 - FY, 2020), %

(9%)

Gross profit (FY, 2020)

2.9b

Gross profit margin (FY, 2020), %

43%

Net income (FY, 2020)

(531.0m)

EBIT (FY, 2020)

(482.0m)

Market capitalization (7-May-2021)

32.1b

Closing stock price (7-May-2021)

64.2

Cash (31-Dec-2020)

1.6b

EV

35.0b
Alcon's current market capitalization is CHF32.1 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

7.2b7.5b6.8b

Revenue growth, %

5%5%(9%)

Cost of goods sold

4.0b3.8b3.9b

Gross profit

3.2b3.7b2.9b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

1.8b1.8b1.8b1.8b1.9b1.9b1.8b1.2b1.8b

Cost of goods sold

913.0m942.0m1.2b972.0m956.0m918.0m969.0m869.0m990.0m

Gross profit

867.0m878.0m568.0m852.0m947.0m950.0m872.0m345.0m848.0m

Gross profit Margin, %

49%48%32%47%50%51%47%28%46%
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

227.0m822.0m1.6b

Accounts Receivable

1.3b1.4b1.4b

Inventories

1.4b1.5b1.6b

Current Assets

3.4b4.2b5.0b
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

721.0m792.0m760.0m1.3b1.4b

Accounts Receivable

1.4b1.4b1.4b1.2b1.3b

Inventories

1.5b1.5b1.5b1.7b1.6b

Current Assets

4.1b4.2b4.1b4.6b4.8b
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(227.0m)(656.0m)(531.0m)

Depreciation and Amortization

1.6b1.5b1.6b

Inventories

(150.0m)(108.0m)(159.0m)

Accounts Payable

44.0m84.0m(21.0m)
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

53.0m(154.0m)(109.0m)(499.0m)(565.0m)(57.0m)(479.0m)(626.0m)

Depreciation and Amortization

615.0m1.3b348.0m709.0m1.1b380.0m779.0m1.2b

Cash From Operating Activities

555.0m914.0m30.0m301.0m574.0m30.0m58.0m384.0m

Purchases of PP&E

(179.0m)(316.0m)(99.0m)(206.0m)(314.0m)(90.0m)(168.0m)(269.0m)
Show all financial metrics

Alcon Revenue Breakdown

Embed Graph

Alcon revenue breakdown by business segment: 26.9% from Contact lenses, 17.8% from Ocular health, 28.6% from Consumables (Surgical), 9.2% from Equipment/other (Surgical), 16.5% from Implantables (Surgical) and 1.0% from Other

Alcon revenue breakdown by geographic segment: 43.5% from United States, 9.5% from Japan, 5.6% from China and 41.3% from Other

Alcon Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

SecurityScorecard logo

Alcon Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Alcon Online and Social Media Presence

Embed Graph

Alcon Company Culture

  • Overall Culture

    A

    77/100

  • CEO Rating

    C+

    68/100

  • Compensation

    B+

    75/100

  • Diversity

    A+

    79/100

Learn more on Comparably

Alcon News and Updates

Alcon: Patient Package Support

Alcon has launched Precision1, a daily disposable contact lens made from silicone hydrogel that is available in sphere and toric

Alcon Announces Broad Retail Availability of Pataday Once Daily Relief Extra Strength in the U.S.

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that Pataday® Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%) is now available in-store and online at U.S. retailers, following its 2020 approval by…

J&J Accuses Alcon of 'Grand and Shocking' Laser Surgery Code Theft

Johnson & Johnson has accused rival Alcon of stealing computer code used in laser eye surgery on a "grand and shocking scale," asking a federal judge to block sales and imports of Alcon cataract surgery products

Alcon Canada Introduces the Clareon IOL with the AutonoMe Preloaded Intraocular Lens Delivery System Français

Alcon, the global leader in eye care, is pleased to announce a nationwide launch of the Clareon® intraocular lens (IOL) with the AutonoMe® delivery system in Canada. AutonoMe is the first-and-only automated, disposable, preloaded IOL delivery system that enables precise delivery of the IOL into the …

Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off

Novartis positioned for sustained growth, including plans to improve Innovative Medicines core margins into mid-30s by 2022.read more

Novartis's Alcon spinoff ousts Baer from Swiss benchmark SMI

Novartis's spinoff of its eyecare division Alcon, set for Tuesday April 9, marks the largest Swiss stock deal in a decade and forces a reshuffle of the benchmark Swiss Market Index (SMI) as private bank Julius Baer gets booted out.
Show more

Alcon Frequently Asked Questions

  • When was Alcon founded?

    Alcon was founded in 1945.

  • Who are Alcon key executives?

    Alcon's key executives are David Endicott, Ian Bell and Heather Attra.

  • How many employees does Alcon have?

    Alcon has 22,142 employees.

  • What is Alcon revenue?

    Latest Alcon annual revenue is $6.8 b.

  • What is Alcon revenue per employee?

    Latest Alcon revenue per employee is $308.6 k.

  • Who are Alcon competitors?

    Competitors of Alcon include NIDEK, Haag-Streit Group and Allergan.

  • Where is Alcon headquarters?

    Alcon headquarters is located at Chemin de Blandonnet 8, Vernier.

  • Where are Alcon offices?

    Alcon has offices in Vernier, Cointrin, Fribourg, Schaffhausen and in 25 other locations.

  • How many offices does Alcon have?

    Alcon has 29 offices.